Metformin suppresses gastric cancer progression by disrupting the STAT1-PRMT1 axis.

[1]  Yezhong Wang,et al.  PRMT1 in human neoplasm: cancer biology and potential therapeutic target , 2024, Cell communication and signaling : CCS.

[2]  Balachandran Manavalan,et al.  Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis , 2023, International journal of biological sciences.

[3]  E. Fornal,et al.  The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. , 2023, Biochemical pharmacology.

[4]  Ruifeng Xu,et al.  Gastric cancer treatment: recent progress and future perspectives , 2023, Journal of Hematology & Oncology.

[5]  G. Freeman,et al.  PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity , 2023, Nature communications.

[6]  Ying Zhang,et al.  HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives , 2022, Biomarker Research.

[7]  Xiumin Wang,et al.  MiR-574-3p inhibits glucose toxicity-induced pancreatic β-cell dysfunction by suppressing PRMT1 , 2022, Diabetology & Metabolic Syndrome.

[8]  M. Garnett,et al.  Can Drug Repurposing Accelerate Precision Oncology? , 2022, Cancer discovery.

[9]  Y. Bao,et al.  Low-dose metformin targets the lysosomal AMPK pathway through PEN2 , 2022, Nature.

[10]  P. Shah,et al.  Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1 , 2022, The Journal of clinical investigation.

[11]  Shemin Lu,et al.  PDGF-BB induces PRMT1 expression through ERK1/2 dependent STAT1 activation and regulates remodeling in primary human lung fibroblasts. , 2021, Cellular signalling.

[12]  W. Wang,et al.  Silencing miR-181b-5p upregulates PIAS1 to repress oxidative stress and inflammatory response in rats with alcoholic fatty liver disease through inhibiting PRMT1. , 2021, International immunopharmacology.

[13]  C. Tseng.  Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus , 2021, Biomolecules.

[14]  Lianmei Zhao,et al.  Advances in clinical immunotherapy for gastric cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[15]  C. Tseng.  Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus , 2021, Biomolecules.

[16]  Huiling Yang,et al.  CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer , 2021, Theranostics.

[17]  C. Tseng.  The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature , 2021, Biomolecules.

[18]  C. Tseng.  Metformin and primary bone cancer risk in Taiwanese patients with type 2 diabetes mellitus. , 2021, Bone.

[19]  Dawang Zhou,et al.  OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis , 2021, Advanced science.

[20]  Melissa J. Davis,et al.  PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling , 2021, Genome medicine.

[21]  Xinwei Han,et al.  Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression , 2021, Journal of cellular and molecular medicine.

[22]  Shemin Lu,et al.  mTOR regulates PRMT1 expression and mitochondrial mass through STAT1 phosphorylation in hepatic cell. , 2021, Biochimica et biophysica acta. Molecular cell research.

[23]  Kaixian Chen,et al.  PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma , 2021, Theranostics.

[24]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[25]  Priya Mondal,et al.  Progress and Promises of Epigenetic Drugs and Epigenetic Diets in Cancer Prevention and Therapy: A Clinical Update. , 2020, Seminars in cancer biology.

[26]  A. Vlahou,et al.  Drug repurposing in oncology. , 2020, The Lancet. Oncology.

[27]  C. Tseng.  Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes , 2020, Frontiers in Oncology.

[28]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[29]  E. Nice,et al.  Overcoming cancer therapeutic bottleneck by drug repurposing , 2020, Signal Transduction and Targeted Therapy.

[30]  Dahai Zheng,et al.  LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis , 2020, Cell cycle.

[31]  Ning Wang,et al.  Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy , 2020, Molecular Cancer.

[32]  J. Mills,et al.  A Metformin-Responsive Metabolic Pathway Controls Distinct Steps in Gastric Progenitor Fate Decisions and Maturation. , 2020, Cell stem cell.

[33]  A. Harris,et al.  Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin , 2019, British Journal of Cancer.

[34]  Dakeun Lee,et al.  PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin , 2019, Journal of Experimental & Clinical Cancer Research.

[35]  D. Xie,et al.  PRMT1 promotes pancreatic cancer growth and predicts poor prognosis , 2019, Cellular Oncology.

[36]  Yue Zhao,et al.  PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation , 2019, Cell Death & Disease.

[37]  A. Wong,et al.  Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. , 2018, Journal of the National Cancer Institute.

[38]  C. Tseng.  Metformin and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. , 2018, Pancreas.

[39]  C. Tseng.  Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus. , 2018, Metabolism: clinical and experimental.

[40]  Jun Yu,et al.  CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis , 2018, Oncogene.

[41]  C. Tseng.  Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[42]  A. Burlingame,et al.  Arginine methylation of SMAD7 by PRMT1 in TGF-β–induced epithelial–mesenchymal transition and epithelial stem-cell generation , 2018, The Journal of Biological Chemistry.

[43]  Jianming Xu,et al.  A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer , 2018, Gastric Cancer.

[44]  C. Tseng.  Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. , 2017, Diabetes & metabolism.

[45]  C. Tseng,et al.  Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus , 2016, Aging.

[46]  Xiaoming Li,et al.  miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1. , 2015, Biochemical and biophysical research communications.

[47]  C. Tseng.  Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus , 2015, Diabetes/metabolism research and reviews.

[48]  C. Tseng.  Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. , 2014, European journal of cancer.

[49]  C. Tseng.  Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes , 2014, Breast Cancer Research and Treatment.

[50]  A. Burlingame,et al.  Arginine Methylation Initiates BMP-Induced Smad Signaling. , 2013, Molecular cell.

[51]  C. Tseng.  Diabetes, Insulin Use, and Gastric Cancer: A Population-based Analysis of the Taiwanese , 2013, Journal of clinical gastroenterology.

[52]  C. Tseng.  Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. , 2012, European journal of endocrinology.

[53]  G. Park,et al.  Changes in the arginine methylation of organ proteins during the development of diabetes mellitus. , 2011, Diabetes research and clinical practice.

[54]  C. Tseng.  Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan , 2010, Gut.

[55]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[56]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[57]  H. Tomita,et al.  Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells , 2003, Hypertension.

[58]  T. Decker,et al.  Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons , 2003, EMBO reports.

[59]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[60]  S. Clarke,et al.  The Mammalian Immediate-early TIS21 Protein and the Leukemia-associated BTG1 Protein Interact with a Protein-arginine N-Methyltransferase* , 1996, The Journal of Biological Chemistry.

[61]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[62]  J. Darnell,et al.  A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. , 1993, Science.